NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Park Medi World FY26 Results: Total Assets Surge to ₹9,167 Mn; Significant Deleveraging Reported
Park Medi World Limited reported a massive expansion in its balance sheet for the financial year ended March 31, 2026, with total assets rising from ₹3,196.28 million to ₹9,167.56 million. The company's equity base saw a substantial jump to ₹8,600.24 million from ₹1,141.86 million, likely driven by a major capital infusion or IPO during the year. Notably, the company significantly deleveraged its balance sheet, reducing non-current borrowings from ₹504.66 million to just ₹47.30 million. High liquidity is evident with cash and bank balances skyrocketing to over ₹3,900 million, positioning the company for aggressive future growth.
முக்கிய அம்சங்கள்
Total Assets grew by 186% YoY to ₹9,167.56 million as of March 31, 2026.Total Equity increased nearly 7.5x to ₹8,600.24 million, significantly strengthening the capital structure.Non-current borrowings were reduced by over 90% to ₹47.30 million from ₹504.66 million.Cash and bank balances surged to ₹3,922 million compared to just ₹5.23 million in the previous year.Mr. Manoj Khanna transitioned from CHRO to Regional Head, ceasing to be Senior Management Personnel.
👀 கவனிக்க வேண்டியவை
The company has achieved a remarkably strong and liquid balance sheet with minimal debt, which is highly favorable for the healthcare sector. Investors should look for management commentary on the deployment of the ₹3,900 million cash reserve for hospital expansions or acquisitions.
Parag Milk Foods Launches Avvatar Protein Cold Coffee; New-Age Segment Grew 91% YoY in FY26
Parag Milk Foods has entered the high-growth ready-to-drink (RTD) protein segment through a strategic partnership with Tetra Pak. The company launched Avvatar Protein Cold Coffee, priced at ₹120, offering 15g of protein per 250ml pack with no added sugar. This launch follows a strong performance in FY26, where the company's new-age business segment, including the Avvatar brand, recorded a 91% year-on-year growth. The product aims to address the 73% protein deficiency in India by integrating nutrition into a familiar daily beverage format.
முக்கிய அம்சங்கள்
Launched India's first RTD protein cold coffee in Tetra Prisma Aseptic 250E packaging priced at ₹120Each 250ml pack delivers 15g of protein with no added sugar or artificial sweetenersThe Avvatar brand and new-age business segment reported a significant 91% YoY growth in FY26Strategic collaboration with Tetra Pak for premium, recyclable, and ergonomic packaging to enhance shelf appealTargets a massive market opportunity as nearly 73% of the Indian population remains protein deficient
👀 கவனிக்க வேண்டியவை
Investors should track the adoption of the Avvatar RTD range as it represents a high-margin expansion into the functional beverage space. The 91% growth in the new-age segment indicates strong brand equity that could drive future valuation re-rating.
Paradeep Phosphates Recommends ₹1.50 Dividend and Approves FY26 Audited Results
Paradeep Phosphates Limited (PPL) has recommended a dividend of ₹1.50 per equity share for the financial year ended March 31, 2026. The Board approved the audited financial results for FY26, which incorporate the retrospective impact of the merger with Mangalore Chemicals & Fertilizers Limited (MCFL) from April 1, 2024. Mrs. Rita Menon has been re-appointed as an Independent Director for a second three-year term, ensuring board continuity. The statutory auditors have issued an unmodified opinion on the financial statements, indicating healthy reporting standards.
முக்கிய அம்சங்கள்
Recommended a dividend of ₹1.50 per equity share of ₹10 each for the financial year 2025-26.Approved audited standalone and consolidated financial results for the year ended March 31, 2026.Re-appointed Mrs. Rita Menon as an Independent Director for a second term of 3 years effective June 27, 2026.Financial results restated to include the impact of the MCFL merger from the retrospective appointed date of April 1, 2024.Statutory auditors BSR & Co. LLP issued an audit report with an unmodified opinion for FY 2025-26.
👀 கவனிக்க வேண்டியவை
The dividend recommendation and clean audit report are positive signals for shareholders. Investors should analyze the consolidated performance to gauge the synergy benefits and growth trajectory following the MCFL merger.
Paradeep Phosphates Recommends Rs 1.50 Final Dividend for FY 2025-26
The Board of Paradeep Phosphates has recommended a final dividend of Rs 1.50 per equity share for the financial year ended March 31, 2026. The company's annual financial results now fully incorporate the impact of the merger with Mangalore Chemicals & Fertilizers Limited (MCFL), effective retrospectively from April 1, 2024. Statutory auditors have issued a clean, unmodified opinion on the financial statements. Additionally, the board approved the re-appointment of Mrs. Rita Menon as an Independent Director for a second three-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs 1.50 per equity share of face value Rs 10 each.Financial results restated to include MCFL merger impact from the appointed date of April 1, 2024.Statutory auditors BSR & Co. LLP issued an unmodified audit report for FY 2025-26.Re-appointed Mrs. Rita Menon as an Independent Director for a second term of 3 years effective June 27, 2026.
👀 கவனிக்க வேண்டியவை
Investors should track the record date for the Rs 1.50 dividend and monitor the post-merger operational synergies with MCFL which are now reflected in the audited accounts.
Parag Milk Foods FY26 PAT Rises 19% to ₹141 Cr; New Age Business Grows 91%
Parag Milk Foods reported a strong FY26 with record revenue of ₹3,818 crore, up 11% YoY, and a 19% increase in PAT (before exceptional items) to ₹141 crore. Despite a 15% YoY surge in milk procurement prices to ₹42/litre in Q4, the company expanded its gross margins to 28% through a premium product mix and calibrated price hikes. The high-margin 'New Age' segment (Avvatar and Pride of Cows) showed exceptional momentum, growing 91% during the year and now contributing 10% to total turnover. The company also strengthened its balance sheet through equity infusion via warrants and FCCB conversions.
முக்கிய அம்சங்கள்
FY26 Revenue reached ₹3,818 crore (up 11% YoY) with PAT before exceptional items at ₹141 crore (up 19% YoY).New Age business (Avvatar & Pride of Cows) grew 91% in FY26, contributing 10% to total revenue and hitting ₹100 crore quarterly run-rate.Q4 FY26 Gross Margins improved by 130 bps YoY to 28.0% despite milk prices rising 15% YoY to ₹42/litre.Core categories (Ghee, Cheese, Paneer) grew 16% in value for FY26, maintaining a dominant 60% share of the business.Cash flow from operations stood at ₹149 crore for FY26, while the capital structure was bolstered by equity infusions.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's successful premiumization strategy and the rapid scaling of the high-margin New Age segment. The ability to expand margins despite inflationary milk prices suggests strong pricing power and a favorable shift in product mix.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Parag Milk Foods FY26 Revenue at ₹3,742 Cr; Recommends ₹1.10 Dividend and Allots 10L ESOP Shares
Parag Milk Foods reported a total revenue of ₹3,742.03 crores for FY26, with Q4 revenue standing at ₹946.17 crores. The Board recommended a final dividend of ₹1.10 per share (11% of face value) for the fiscal year, subject to shareholder approval. To support employee incentives, 1,000,000 equity shares were allotted to the ESOP Trust, increasing the total paid-up capital to ₹126.11 crores. The company also moved a promoter group entity with zero holding to the public category, streamlining its shareholding structure.
முக்கிய அம்சங்கள்
Annual revenue from operations reached ₹3,742.03 crores for the financial year ended March 31, 2026.Board recommended a final dividend of ₹1.10 per equity share (11% of face value).Allotment of 10,00,000 equity shares to the ESOP Trust under the 2022 scheme.Q4 FY26 standalone profit after tax recorded at ₹28.28 crores on revenue of ₹946.17 crores.Total paid-up equity share capital increased to ₹126,10,95,540 following the ESOP allotment.
👀 கவனிக்க வேண்டியவை
The steady revenue growth and dividend recommendation are positive indicators for shareholders; investors should monitor the impact of ESOP dilution on future EPS and track margin performance.
Parag Milk Foods Credit Rating Upgraded to IND BBB+; Outlook Stable
India Ratings and Research has upgraded Parag Milk Foods' credit rating for bank facilities and Non-Convertible Debentures (NCDs) to 'IND BBB+' from 'IND BBB'. The short-term rating has also seen an upgrade to 'IND A2' from 'IND A3+', indicating improved liquidity and creditworthiness. The rating action covers bank facilities worth INR 6,000 million and NCDs worth INR 810 million. This upgrade suggests a strengthening financial profile and potentially lower future borrowing costs for the dairy major.
முக்கிய அம்சங்கள்
Long-term rating for INR 6,000 million bank loan facilities upgraded to IND BBB+/Stable.NCD rating for INR 810 million (reduced from INR 1,050 million) upgraded to IND BBB+.Short-term bank loan rating upgraded from IND A3+ to IND A2.Issuer rating upgraded to IND BBB+/Stable prior to its withdrawal at the company's request.
👀 கவனிக்க வேண்டியவை
The upgrade is a positive indicator of the company's debt-servicing capability and financial health. Investors should monitor the impact on interest costs and overall profitability in the next few quarters.
BIL Vyapar Cites CIRP for Non-Applicability of Corporate Governance Reporting for Q4 FY26
BIL Vyapar Limited (formerly Binani Industries Limited) has informed stock exchanges that Regulation 27 regarding Corporate Governance reporting is not applicable for the quarter and year ended March 31, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP), which commenced on January 13, 2026. Ms. Rachana Jhunjhunwala has been appointed as the Resolution Professional to oversee the company's affairs. Under SEBI Regulation 15, companies under CIRP are exempt from specific governance compliance filings.
முக்கிய அம்சங்கள்
Company entered Corporate Insolvency Resolution Process (CIRP) effective January 13, 2026.Ms. Rachana Jhunjhunwala appointed as the Resolution Professional for the insolvency proceedings.Exemption from Regulation 27 (Corporate Governance) claimed for the fourth quarter and full year ended March 31, 2026.The filing follows SEBI (LODR) Regulation 15 which provides relief to companies under insolvency.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company is in insolvency proceedings, which often results in significant equity dilution or delisting. Monitor the progress of the resolution plan for any updates on potential recovery value for shareholders.
BIL Vyapar CoC Discusses Resolution Plan Extension and Valuation in 8th Meeting
BIL Vyapar Limited, currently under the Corporate Insolvency Resolution Process (CIRP), held its 8th Committee of Creditors (CoC) meeting on April 30, 2026. The CoC discussed a request from a prospective resolution applicant for an extension of time to submit a resolution plan. The meeting also addressed the appointment of a co-ordinating valuer and the approval of CIRP costs. Furthermore, the committee is seeking a new accountant to prepare accounts for audit as the previous auditor expressed inability to perform the task.
முக்கிய அம்சங்கள்
Prospective resolution applicant has requested an extension of time for the submission of the Resolution Plan.CoC noted the valuation methodology and approved the appointment of a Co-ordinating Valuer.Committee of Creditors officially took note of and approved the CIRP costs incurred.Search for a new accountant initiated to prepare accounts for audit purposes following the withdrawal of the previous auditor.
👀 கவனிக்க வேண்டியவை
Equity shareholders should exercise extreme caution as CIRP proceedings often lead to significant capital erosion or delisting. Monitor the outcome of the resolution plan submission and the valuation reports to understand potential recovery values.
SPARC to Sell Priority Review Voucher for US $195 Million
Sun Pharma Advanced Research Company (SPARC) has signed a definitive agreement to sell its Rare Paediatric Disease Priority Review Voucher (PRV) for $195 million. The PRV was originally granted by the US FDA following the approval of Sezaby for neonatal seizures. This transaction provides a significant non-dilutive cash infusion, which the company plans to use to accelerate its clinical pipeline and innovation strategy. The deal is currently subject to customary closing conditions, including US antitrust clearance.
முக்கிய அம்சங்கள்
Monetization of Priority Review Voucher (PRV) for a total value of US $195 millionPRV was earned through the FDA approval of Sezaby for treating neonatal seizuresProceeds to be utilized for accelerating development of pipeline assets and innovation strategyTransaction is subject to the Hart-Scott-Rodino (HSR) Antitrust Improvements Act waiting periodStifel acted as the exclusive financial advisor for this asset sale
👀 கவனிக்க வேண்டியவை
This is a major liquidity event that provides SPARC with substantial capital to fund its R&D without equity dilution. Investors should monitor how this cash is deployed across their clinical pipeline to drive long-term value.
Paradeep Phosphates Shareholders Approve MD Re-appointment and New Joint MD
Paradeep Phosphates Limited has successfully passed three special resolutions via postal ballot, ensuring leadership continuity. Shareholders approved the re-appointment of Mr. N Suresh Krishnan as Managing Director with 97.99% votes in favor. The appointment of Mr. K K Rajeev Nambiar as Joint Managing Director and Mr. Marco Philippus Ardeshir Wadia as an Independent Director were also approved. However, significant institutional dissent was observed, particularly regarding the Independent Director appointment where 54.31% of institutional votes were cast against the resolution.
முக்கிய அம்சங்கள்
Re-appointment of Mr. N Suresh Krishnan as Managing Director passed with 97.99% total votes in favor.Appointment of Mr. K K Rajeev Nambiar as Joint Managing Director approved with 91.11% total votes.Appointment of Mr. Marco Philippus Ardeshir Wadia as Independent Director passed with 85.29% total votes.Institutional investors showed significant resistance, with 54.31% of their votes against the Independent Director appointment and 32.82% against the Joint MD.Total of 81.96 crore votes were polled out of 103.81 crore outstanding shares, representing a 78.95% turnout.
👀 கவனிக்க வேண்டியவை
While management continuity is positive, investors should monitor the reasons behind the high institutional dissent regarding the Independent Director and Joint MD appointments for potential governance concerns.
Paras Defence Signs MoU with Complus Systems and JV Micronics for Anechoic Chambers
Paras Defence and Space Technologies has entered into a tripartite Memorandum of Understanding (MoU) with Complus Systems and JV Micronics to target the Anechoic and Semi-Anechoic Chambers market. Paras will act as the consortium leader, overseeing the design, manufacturing, and strategic direction of these specialized testing facilities. The partnership leverages Complus's instrumentation expertise and JV Micronics's RF absorber manufacturing to pursue domestic and international opportunities. This strategic move expands Paras's high-tech infrastructure portfolio in the defense and electronics sectors.
முக்கிய அம்சங்கள்
Paras Defence to lead the consortium for design, development, and installation of Anechoic Chambers.Partnership includes Complus Systems for instrumentation and JV Micronics for RF absorber manufacturing.The collaboration targets both Indian and international markets for specialized testing infrastructure.Paras will specifically manufacture Chambers, Filters, and Engineered Points of Entry.MoU aims to integrate technical expertise to provide end-to-end solutions in the RF testing domain.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step towards diversifying the company's high-end engineering portfolio. Monitor for future announcements regarding specific contract wins or order book additions resulting from this consortium.
BIL Vyapar Limited Schedules 8th Committee of Creditors Meeting for April 22, 2026
BIL Vyapar Limited, formerly known as Binani Industries Limited, has announced the 8th meeting of its Committee of Creditors (CoC) to be held on April 22, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. This meeting is a critical step in the ongoing restructuring process to address the company's debt obligations. Investors should remain aware that the company's management is currently overseen by a Resolution Professional.
முக்கிய அம்சங்கள்
8th meeting of the Committee of Creditors (CoC) scheduled for April 22, 2026Company is currently under the Corporate Insolvency Resolution Process (CIRP)Disclosure made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015BIL Vyapar Limited was formerly known as Binani Industries Limited (NSE: BILVYAPAR)
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as equity value is frequently diluted or eliminated during insolvency proceedings. Monitor the outcome of the CoC meeting for updates on potential resolution plans or liquidation risks.
Parsvnath Completes 20.67-Acre 'Saatvik Green NX' Project in Indore
Parsvnath Developers has announced the successful completion of its 'Saatvik Green NX' project in Indore, covering 20.67 acres (83,670 Sqm). The project, which commenced in April 2024, has received its official Completion Certificate from the Office of Collector, District Indore. It features 473 residential plots categorized into Silver, Gold, and Platinum segments. This completion is part of the company's 'MISSION POSSESSION' strategy, focusing on the execution and delivery of ongoing projects to improve its operational track record.
முக்கிய அம்சங்கள்
Completion of 20.67-acre residential plot project 'Saatvik Green NX' in IndoreDelivery of 473 residential plots across Silver, Gold, and Platinum categoriesProject execution completed within a 24-month timeframe from April 2024 to April 2026Official Completion Certificate received from the Office of Collector, District Indore
👀 கவனிக்க வேண்டியவை
This development indicates improved execution capabilities for Parsvnath; investors should monitor if this translates into better cash flow and debt reduction in future earnings reports.
Apeejay Surrendra Park Hotels Signs 2 New Management Agreements in Ayodhya and Ujjain
Apeejay Surrendra Park Hotels Limited (ASPHL) has strategically expanded its footprint in the spiritual tourism sector by signing two new management agreements. The company will develop 'Zone Connect by The Park' properties in Ayodhya (56 rooms) and Ujjain (64 rooms), targeting high-demand pilgrimage circuits. These agreements follow an asset-light management model, which is expected to enhance operational efficiency and brand presence without heavy capital expenditure. This expansion brings the company's diverse portfolio closer to its goal of capturing the growing influx of domestic and international religious tourists.
முக்கிய அம்சங்கள்
Signed two hotel management agreements for Zone Connect by The Park in Ayodhya and UjjainAyodhya property features 56 rooms and is located 4.9 km from Ram JanmabhoomiUjjain property features 64 rooms and is located 8 km from Mahakaleshwar Jyotirlinga TempleExpansion utilizes an asset-light management model to strengthen the existing portfolio of 39 hotelsProperties will include full-service amenities like Café C, swimming pools, and banquet facilities
👀 கவனிக்க வேண்டியவை
Investors should look favorably on this expansion into high-growth spiritual tourism hubs via an asset-light model. Monitor the company's ability to maintain occupancy rates and ADRs in these competitive religious circuits as they become operational.
Sai Parenterals Approves INR 11.91 Cr Loan for Australian Subsidiary Expansion
The Board of Sai Parenterals has approved an unsecured loan of up to AUD 1.75 million (approximately INR 11.91 crore) to its wholly-owned subsidiary, Sai Singapore Pte. Ltd. These funds are designated for downstream investment into Noumed Pharmaceuticals PTY Limited, the company's step-down subsidiary in Australia. This move signifies a strategic effort to bolster its international operations and provide financial support to its Australian business unit. The transaction highlights the company's focus on global market penetration through its existing subsidiary network.
முக்கிய அம்சங்கள்
Approved financial assistance via unsecured loan not exceeding AUD 1.75 million or SGD 1.610 million.Total investment value is approximately INR 11,91,40,000.Funds to be routed through Sai Singapore Pte. Ltd. to Noumed Pharmaceuticals PTY Limited, Australia.The board meeting concluded on April 20, 2026, confirming the strategic capital allocation.
👀 கவனிக்க வேண்டியவை
Investors should monitor the revenue contribution from the Australian subsidiary in future earnings to evaluate the effectiveness of this capital infusion. The stock remains a positive watch for those tracking the company's international growth trajectory.
Uniparts India Receives Relief as ₹25.8 Crore Tax Demand is Fully Deleted
Uniparts India Limited has successfully resolved a significant tax dispute for the Assessment Year 2024-25. The Assistant Commissioner of Income Tax issued a rectification order that completely deletes a previously outstanding tax demand of INR 25.8 crore. This development removes a substantial potential liability from the company's books, improving financial clarity. The order was received by the company on April 17, 2026, following an earlier assessment order.
முக்கிய அம்சங்கள்
Tax demand of INR 25,79,86,410 (₹25.8 crore) has been fully deleted by tax authorities.Rectification order issued for Assessment Year 2024-25 under Section 154 of the Income Tax Act.The order follows a previous assessment update communicated on February 12, 2026.The deletion of this demand removes a significant legal and financial overhang for the company.
👀 கவனிக்க வேண்டியவை
This is a positive development as it eliminates a major contingent liability and protects the company's cash flows. Investors should view this as a reduction in regulatory risk for the stock.
Paras Defence Signs 10-Year Exclusive Agreement with Northstar USA for Air-to-Air Refueling
Paras Defence and Space Technologies has entered into a strategic 10-year exclusive agreement with US-based Bandak Aviation Inc. (Northstar). The collaboration aims to supply and support air-to-air refueling systems and accessories specifically for the Indian Armed Forces. Under this agreement, Paras will develop local facilities and depot-level capabilities to provide maintenance and support services. This partnership positions Paras as a key player in a specialized high-tech aerospace niche within the Indian defense market.
முக்கிய அம்சங்கள்
Signed a 10-year exclusive agreement with Bandak Aviation Inc. DBA Northstar, USA.Focuses on air-to-air refueling systems, accessories, and associated services for Indian Armed Forces.Paras will develop specialized facilities and depot-level capabilities for product support in India.Exclusive nature of the deal ensures Paras is the sole Indian partner for Northstar's specific product line.Strengthens the company's position in the high-entry-barrier aerospace and defense technology sector.
👀 கவனிக்க வேண்டியவை
This is a positive development that enhances Paras's long-term revenue visibility and technical expertise. Investors should monitor for specific contract announcements or order book additions resulting from this partnership.
BIL Vyapar Limited Schedules 7th Committee of Creditors Meeting for April 13, 2026
BIL Vyapar Limited, formerly known as Binani Industries Limited, has announced the 7th meeting of its Committee of Creditors (CoC) scheduled for April 13, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. This meeting is a critical step in determining the future of the company, including potential resolution plans or liquidation. As the company is under CIRP, the management is currently overseen by a Resolution Professional, and the powers of the Board of Directors remain suspended.
முக்கிய அம்சங்கள்
7th meeting of the Committee of Creditors (CoC) to be held on April 13, 2026Company is currently under Corporate Insolvency Resolution Process (CIRP)Disclosure made pursuant to Regulation 30 and Para 16(g) of Part A of Schedule III of SEBI LODRBIL Vyapar Limited was formerly known as Binani Industries Limited (NSE: BILVYAPAR, BSE: 500059)
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as equity shareholders typically face significant value erosion or total loss during insolvency proceedings. Monitor the outcomes of CoC meetings for any updates on resolution plans or liquidation orders.
Binani Industries has responded to NSE's clarification request regarding its Q2 FY25 financial results, citing auditor errors for subsidiary count discrepancies and technical faults for filing delays. The company's financial position is extremely weak, with accumulated losses of ₹21,682 lakhs and a fully eroded net worth. Liabilities exceed total assets by ₹18,543 lakhs, leading auditors to conclude that the 'going concern' assumption is no longer valid. Consequently, the financial statements have been prepared on a liquidation basis, reflecting severe financial distress.
முக்கிய அம்சங்கள்
Accumulated losses reached ₹21,682 lakhs with liabilities exceeding assets by ₹18,543 lakhs as of September 30, 2024.Auditors stated the 'going concern' assumption is inappropriate and financials are prepared on a liquidation basis.Outstanding corporate guarantees and letters of comfort total approximately ₹13,196 lakhs for erstwhile subsidiaries.Reported a standalone net loss of ₹54 lakhs for Q2 FY25 on zero operating income.Clarified that one subsidiary was struck off in FY 2023-24, leading to previous reporting errors by auditors.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company's net worth is fully eroded and it is being valued on a liquidation basis. The significant contingent liabilities and lack of a clear business plan suggest a very high risk of capital loss.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
